Chemotherapeutic Potential of Fluorouracil‐Platinum (IV) Prodrugs Against Cisplatin‐Resistant Colorectal Cancer Cells
Chemistry – A European Journal · 13.08.2026 · 32 (30)
DOI: 10.1002/chem.202503422 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry – A European Journal, online erschienen am 27.02.2026. Verfasst von Maria George Elias und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Engineering, Computing and Science, Western Sydney University, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Prodrugs, Fluorouracil, Colorectal Neoplasms, Cisplatin. Die Arbeit nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: School of Medicine, Western Sydney University, Western Sydney University.
Abstract (Originalsprache)
Fluorouracil‐platinum(IV) prodrugs represent a novel class of multimechanistic chemotherapeutics with enhanced anticancer potential. The prodrugs Pt IV P‐5FUMeOBut and Pt IV 56‐5FUMeOBut were actualized by derivatising the clinical drug 5‐fluorouracil (5FU) and coordinating it to platinum(IV) complexes, leveraging the established cytotoxicity of their platinum(II) precursors, Pt II PHEN SS and Pt II 56ME SS . The rationale behind this design is to combine the DNA synthesis‐disrupting antimetabolite activity of 5FU with platinum‐based cytotoxicity, aiming to enhance therapeutic efficacy. This study evaluates the in vitro potency of Pt IV P‐5FUMeOBut and Pt IV 56‐5FUMeOBut in colorectal cancer models, assessing their cellular uptake, cytotoxicity, and effects in 3D spheroid cultures. Comparative analyses with cisplatin and 5FU explore their impact on cell survival, reactive oxygen species production, mitochondrial membrane potential, and cell‐cycle progression. Mechanistic insights are further examined through apoptosis and necrosis assays, proteomic profiling, and western blot analysis of key signalling pathways. These findings contribute to the preclinical development of fluorouracil‐platinum(IV) prodrugs as potential candidates for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Engineering, Computing and Science, Western Sydney University, Sydney, New South Wales, Australia.
- Faculty of Health, School of Medicine, Western Sydney University, Sydney, New South Wales, Australia.
- Medical Oncology, Ingham Institute for Applied Medical Research, Liverpool Hospital, Liverpool, New South Wales, Australia.
- Mass Spectrometry Facility, Western Sydney University, Sydney, New South Wales, Australia.
- Nepean Clinical School, Faculty of Medicine and Health, University of Sydney, Kingswood, New South Wales, Australia.
ORCID-Profile: Maria George Elias, Aleen Khoury, Shadma Fatima, Timothy J Mann, Shawan Karan, Meena Mikhael, Paul de Souza, Christopher P Gordon, Kieran F Scott, Janice R Aldrich-Wright
Förderung
- School of Medicine, Western Sydney University
- Western Sydney University
Zitieren
APA
Elias, M. G., Khoury, A., Fatima, S., Mann, T. J., Karan, S., Mikhael, M., de Souza, P., Gordon, C. P., Scott, K. F., & Aldrich-Wright, J. R. (2026). Chemotherapeutic Potential of Fluorouracil‐Platinum (IV) Prodrugs Against Cisplatin‐Resistant Colorectal Cancer Cells. Chemistry – A European Journal, 32(30). https://doi.org/10.1002/chem.202503422
Vancouver
Elias MG, Khoury A, Fatima S, Mann TJ, Karan S, Mikhael M, et al. Chemotherapeutic Potential of Fluorouracil‐Platinum (IV) Prodrugs Against Cisplatin‐Resistant Colorectal Cancer Cells. Chemistry – A European Journal. 2026;32(30). doi:10.1002/chem.202503422
BibTeX
@article{Elias2026,
author = {Elias, Maria George and Khoury, Aleen and Fatima, Shadma and Mann, Timothy J and Karan, Shawan and Mikhael, Meena and de Souza, Paul and Gordon, Christopher P and Scott, Kieran F and Aldrich-Wright, Janice R},
title = {Chemotherapeutic Potential of Fluorouracil‐Platinum (IV) Prodrugs Against Cisplatin‐Resistant Colorectal Cancer Cells},
journal = {Chemistry – A European Journal},
year = {2026},
volume = {32},
number = {30},
doi = {10.1002/chem.202503422}
}
EUVIMED